Acinetobacter baumannii from the one health perspective in Nigeria: A systematic review of literature in the last decade (2011-2021)

S. Ajoseh, K. O. Akinyemi, R. Abegunrin, H. Neubauer, G. Wareth
{"title":"Acinetobacter baumannii from the one health perspective in Nigeria: A systematic review of literature in the last decade (2011-2021)","authors":"S. Ajoseh, K. O. Akinyemi, R. Abegunrin, H. Neubauer, G. Wareth","doi":"10.51585/gjm.2022.3.0018","DOIUrl":null,"url":null,"abstract":"Multidrug drug-resistant (MDR)-Acinetobacter baumannii (A. baumannii) is one of the most feared nosocomial bacterial agents worldwide, and the World Health Organization classified carbapenem-resistant strains as a priority ”1” critical pathogen. In Nigeria, the paucity of information on this pathogen makes it difficult to estimate its potential impact on public health and veterinary medicine. This systemic review was done to prepare an impact assessment for One Health based on the occurrence of A. baumannii in different environments and the antimicrobial resistance. A detailed search of articles on A. baumannii in Nigeria was conducted using search strings in the following databases: PubMed, Scopus, Google search engine, and Google scholars. This study revealed that 14 out of the 36 states in Nigeria reported A. baumannii. Specifically, 19/24 articles described isolates from clinical settings, 4/24 from the environment, and 1/24 from animal sources. A. baumannii occurrence of 9.15% (503/5496) was recorded from 8.4% (418/4950), 16.06% (80/498), and 10.42% (5/48) of samples of clinical, environmental, and animal origin by culture, respectively. The most common antibiotics to which A. baumannii was resistant were chloramphenicol, ampicillin-sulbactam, amoxicillin, amoxicillin-clavulanate, cefuroxime, ceftazidime, ceftriaxone, gentamycin, and tetracycline. Seventeen resistance determinants were described for A. baumannii isolates originating mostly from clinical sources with blaOXA-51 and blaOXA-23 gene makers frequently reported. This study demonstrates the lack of data on A. baumannii from animals. Clinical MDR- A. baumannii isolates, particularly in Intensive Care Units (ICUs), are a severe public health concern in Nigeria. Thus, findings from this review will form a baseline for future surveillance research.","PeriodicalId":222095,"journal":{"name":"German Journal of Microbiology","volume":"22 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"German Journal of Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51585/gjm.2022.3.0018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Multidrug drug-resistant (MDR)-Acinetobacter baumannii (A. baumannii) is one of the most feared nosocomial bacterial agents worldwide, and the World Health Organization classified carbapenem-resistant strains as a priority ”1” critical pathogen. In Nigeria, the paucity of information on this pathogen makes it difficult to estimate its potential impact on public health and veterinary medicine. This systemic review was done to prepare an impact assessment for One Health based on the occurrence of A. baumannii in different environments and the antimicrobial resistance. A detailed search of articles on A. baumannii in Nigeria was conducted using search strings in the following databases: PubMed, Scopus, Google search engine, and Google scholars. This study revealed that 14 out of the 36 states in Nigeria reported A. baumannii. Specifically, 19/24 articles described isolates from clinical settings, 4/24 from the environment, and 1/24 from animal sources. A. baumannii occurrence of 9.15% (503/5496) was recorded from 8.4% (418/4950), 16.06% (80/498), and 10.42% (5/48) of samples of clinical, environmental, and animal origin by culture, respectively. The most common antibiotics to which A. baumannii was resistant were chloramphenicol, ampicillin-sulbactam, amoxicillin, amoxicillin-clavulanate, cefuroxime, ceftazidime, ceftriaxone, gentamycin, and tetracycline. Seventeen resistance determinants were described for A. baumannii isolates originating mostly from clinical sources with blaOXA-51 and blaOXA-23 gene makers frequently reported. This study demonstrates the lack of data on A. baumannii from animals. Clinical MDR- A. baumannii isolates, particularly in Intensive Care Units (ICUs), are a severe public health concern in Nigeria. Thus, findings from this review will form a baseline for future surveillance research.
尼日利亚单一健康视角下的鲍曼不动杆菌:近十年(2011-2021)文献系统综述
多药耐药-鲍曼不动杆菌(鲍曼不动杆菌)是世界范围内最令人恐惧的医院细菌之一,世界卫生组织将碳青霉烯耐药菌株列为优先“1”级关键病原体。在尼日利亚,由于缺乏关于这种病原体的信息,因此难以估计其对公共卫生和兽医的潜在影响。本系统综述的目的是根据鲍曼不动杆菌在不同环境中的发生情况和抗菌素耐药性对One Health的影响进行评估。利用PubMed、Scopus、Google搜索引擎和Google scholars等数据库中的搜索字符串,对尼日利亚的鲍曼不动杆菌相关文章进行了详细的检索。这项研究显示,尼日利亚36个州中有14个州报告了鲍曼不动杆菌。具体来说,19/24的文章描述了来自临床环境的分离株,4/24来自环境,1/24来自动物来源。临床、环境和动物源培养样本中鲍曼不动杆菌的发生率分别为8.4%(418/4950)、16.06%(80/498)和10.42%(5/48),分别为9.15%(503/5496)、9.15%(503/5496)。鲍曼不动杆菌最常见的耐药抗生素是氯霉素、氨苄西林-舒巴坦、阿莫西林、阿莫西林-克拉维酸、头孢呋辛、头孢他啶、头孢曲松、庆大霉素和四环素。鲍曼不动杆菌的17个耐药决定因素主要来自临床来源,blaOXA-51和blaOXA-23基因制造者经常被报道。本研究表明缺乏来自动物的鲍曼不动杆菌数据。临床耐多药-鲍曼不动杆菌分离株,特别是在重症监护病房(icu),是尼日利亚一个严重的公共卫生问题。因此,本综述的发现将为今后的监测研究奠定基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信